Tag: VIVA
New data add to body of research demonstrating safety and effectiveness...
Results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions have just been released as late-breaking data presentations at VIVA 2024...
DRS combination of scaffold and antirestenotic drug will “really advance” treatment...
Principal investigators of the LIFE-BTK randomised controlled trial delve into the technological improvements underpinning the Esprit drug-eluting resorbable scaffold (DRS; Abbott) from its previous...
“First victory” in BTK space demonstrates lessons learned and paves the...
Lawrence Garcia (St Francis Hospital, New York, USA) speaks to Vascular News at VIVA 2023 (30 October–2 November, Las Vegas, USA) on lessons learned...
Optimal management of vascular wounds: Patient-specific decisions and multidisciplinary care are...
Vincent Rowe (University of California Los Angeles, Los Angeles, USA) speaks to Vascular News at VIVA 2023 (30 October–2 November, Las Vegas, USA) on...
Computer-assisted vacuum thrombectomy system for patients with pulmonary embolism demonstrates ‘rapid,...
Patients undergoing computer-assisted vacuum thrombectomy with the Indigo Aspiration System (Penumbra) for pulmonary embolism (PE) showed 2.7% rates of both major adverse events (MAEs)...
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit...
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency...
ILLUMENATE four-year pooled analysis has “brought increased clarity” to the paclitaxel...
Sean Lyden (Cleveland, USA), current VIVA Board president, speaks to Vascular News about his two years at the helm, which began with the “controversy on...
New data reconfirm long-term safety profile of the Philips Stellarex low-dose...
Royal Philips recently announced the four-year results from the ILLUMENATE European randomised controlled trial (EU RCT). The Stellarex drug-coated balloon (DCB) cohort demonstrated similar...
Intact Vascular announces positive one-year data from TOBA II BTK clinical...
Intact Vascular announced the positive one-year results from its Tack optimised balloon angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA)...
VIVA Physicians publishes analysis evaluating mortality and paclitaxel-coated devices
An individual patient-level data (IPD) analysis of the safety of paclitaxel-containing devices (PTXD), conducted by VIVA Physicians, identified an absolute 4.6% increased mortality risk...
Virtual VIVA roundtable addresses COVID-19 pandemic
VIVA Physicians recently hosted a virtual roundtable to address COVID-19. Tony Das (Connected Cardiovascular Care Associates, Dallas and BSW Heart Hospital, Plano, USA), one...
Vascular Leaders Forum discussions seek consensus on paclitaxel
The Vascular Leaders Forum (VLF, 1–2 March, Washington DC, USA), hosted by the non-profit organisation VIVA Physicians, is a special consortium which was called...
Lutonix 014 DCB gathers first randomised evidence of positive safety and...
Six-month outcomes of the Lutonix BTK IDE trial, a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (DCB; BD), has demonstrated that...
Lutonix Global Real-World Registry 24-month outcomes presented at VIVA 2016
Bard has announced the presentation of the final 24-month results from the Lutonix Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 meeting...
Positive late-breaking DANCE clinical trial data presented at VIVA 2016
Christopher Owens, associate professor of Surgery in the Division of Vascular and Endovascular Surgery at the University of California, San Francisco (UCSF), USA, has...
Medtronic Valiant Captivia demonstrates safety and efficacy at three years
Medtronic has announced new data, demonstrating safety and efficacy at three years in acute complicated type B aortic dissection patients treated with the Valiant Captivia thoracic...
One-year Japanese results support use of the Viabahn endoprosthesis to treat...
Gore has announced positive results from a prospective, multicentre investigational device exemption (IDE) clinical study of the Viabahn endoprosthesis with heparin bioactive surface in...
Endologix reports positive clinical data from Ovation LIFE study
Endologix has announced positive clinical data from the Ovation LIFE (Least Invasive Fast-Track EVAR) study. Zvonimir Krajcer, co-director, Peripheral Vascular Disease Service at Texas...
